Champions Oncology Inc.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: championsoncology.com
Peers
Recent Analyst Ratings for Champions Oncology Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2024 | $6.00 | Hold → Buy | Craig Hallum |
Champions Oncology Inc. Press Releases
Fastest customizable press release news feed in the world
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or
Champions Oncology Announces Agreement with Weill Cornell Medicine
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft (PDX) models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and S
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51258, or by access
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024.Fourth Quarter Financial Highlights:Fourth quarter revenue increased 7% to $14 millionAdjusted EBITDA fourth quarter income of $884,000Fourth quarter gross margin on pharmacology services of 49%Fiscal Year 2024 Financial Highlights:Annual revenue of $50.2 million, a decrease of 7% year-over-yearFiscal Year 2024 adjusted EBITDA loss of $3.9 millionFiscal Year 2024 gross margin on pharmacology services of 42%Ro
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 135832. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50895, or b
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024.Third Quarter and Recent Highlights:Third quarter revenue of $12.0 million, a decline of 6%Gross margin declined to 35%College of American Pathologists (CAP) has awarded accreditation to US-based laboratoryRonnie Morris, CEO of Champions, commented, "As discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approxima
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the College of American Pathologists (CAP) has awarded accreditation to its US-based laboratory.This achievement of CAP accreditation continues to strengthen Champions Oncology's reputation as a high-quality, state of the art laboratory providing the highest standards of excellence in histology and immunohistochemistry services. This accreditation further validates Champions' commitment to excellence in designing assays, delivering analysis, and managing data effectively for preclinical stu
Champions Oncology Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Champions Oncology upgraded by Craig Hallum with a new price target
Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00
Roth Capital reiterated coverage on Champions Oncology with a new price target
Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously
Champions Oncology Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $18,750 worth of shares (3,000 units at $6.25), increasing direct ownership by 2% to 192,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $6,150 worth of shares (1,000 units at $6.15), increasing direct ownership by 0.53% to 189,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $12,180 worth of shares (2,000 units at $6.09), increasing direct ownership by 1% to 188,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $18,360 worth of shares (3,000 units at $6.12), increasing direct ownership by 2% to 186,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $2,915 worth of shares (500 units at $5.83), increasing direct ownership by 0.27% to 183,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $12,300 worth of shares (2,500 units at $4.92), increasing direct ownership by 1% to 183,181 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $10,122 worth of shares (2,100 units at $4.82), increasing direct ownership by 1% to 180,681 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Champions Oncology Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Director Breitfeld Philip P.
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
SEC Form 4 filed by Director Sidransky David
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
SEC Form 4 filed by Director Mendelson Daniel Newman
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
SEC Form 4 filed by Director Tobin Scott R
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
SEC Form 4 filed by Director Ackerman Joel
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Director Ackerman Joel exercised 105,137 shares at a strike of $2.63, increasing direct ownership by 12% to 962,134 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
SEC Form 4 filed by Davis Brady
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)
4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)
Champions Oncology Inc. SEC Filings
Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
SEC Form 10-Q filed by Champions Oncology Inc.
10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
SEC Form S-8 filed by Champions Oncology Inc.
S-8 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
Champions Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
Champions Oncology Inc. filed SEC Form 8-K: Leadership Update
8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
SEC Form 10-Q filed by Champions Oncology Inc.
10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
SEC Form DEFA14A filed by Champions Oncology Inc.
DEFA14A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
SEC Form DEF 14A filed by Champions Oncology Inc.
DEF 14A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)
Champions Oncology Inc. Leadership Updates
Live Leadership Updates
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv
Champions Oncology Announces the Addition of Brady Davis as President
HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical
Champions Oncology Announces Addition to Board of Directors
HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented
Champions Oncology Inc. Financials
Live finance-specific insights
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51258, or by access
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024.Fourth Quarter Financial Highlights:Fourth quarter revenue increased 7% to $14 millionAdjusted EBITDA fourth quarter income of $884,000Fourth quarter gross margin on pharmacology services of 49%Fiscal Year 2024 Financial Highlights:Annual revenue of $50.2 million, a decrease of 7% year-over-yearFiscal Year 2024 adjusted EBITDA loss of $3.9 millionFiscal Year 2024 gross margin on pharmacology services of 42%Ro
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 135832. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50895, or b
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024.Third Quarter and Recent Highlights:Third quarter revenue of $12.0 million, a decline of 6%Gross margin declined to 35%College of American Pathologists (CAP) has awarded accreditation to US-based laboratoryRonnie Morris, CEO of Champions, commented, "As discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approxima
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50100, or by accessing the
Champions Oncology Reports Quarterly Revenue of $11.6 Million
HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023.Second Quarter and Recent Highlights:Second quarter revenue of $11.6 million, a decline of 19%Revised fiscal year 2024 revenue guidance to be generally in-line with last year's resultsStrong quarterly bookingsEuropean lab received ISO accreditation and ATS certificationHired Brady Davis as President to develop new strategic initiativesRonnie Morris, CEO of Champions, commented, "As discussed during our
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 589886. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 49578, or by access
Champions Oncology Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.
SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)
SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)
SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)
SEC Form SC 13G filed by Champions Oncology Inc.
SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)
SEC Form SC 13G/A filed by Champions Oncology Inc. (Amendment)
SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)
SEC Form SC 13G filed by Champions Oncology, Inc.
SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)